AbbVie News Center

Home /

Latest news

October 13, 2026

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboi Results build on previously reported week...

October 11, 2026

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and...

October 07, 2026

AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC

Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including...

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

Press Kits

Our press kits are designed to provide journalists with a broad range of background information on our company.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Stay up to date on recent news, articles, and more.

Month Year

Get News Alerts by Email

June 24, 2002

ImmunoGen, Inc. Provides Update on Relationship with GlaxoSmithKline and Also on the Status of Trastuzumab-DM1
June 12, 2002

ImmunoGen, Inc. Taxane Derivatives Show Greater Potency Than Taxol(R) Against Both Taxane-Responsive and Multi-Drug-Resistant Cancer Cell Lines
May 21, 2002

ImmunoGen, Inc. Announces Presentation of Data on Cantuzumab Mertansine at the Annual Meeting of the American Society of Clinical Oncology
May 20, 2002

ImmunoGen, Inc. and British Biotech plc Announce Presentation of Data from Ongoing Phase I/II Clinical Study of huN901-DM1/BB-10901 at the 2002 Meeting of the American Society of Clinical Oncology
May 09, 2002

ImmunoGen, Inc. Reports Third-Quarter Results
February 20, 2002

ImmunoGen and Millennium Sign Exclusive Product License
February 07, 2002

ImmunoGen, Inc. Reports Second-Quarter Results
January 23, 2002

ImmunoGen, Inc. Receives Patent on Taxane Compounds
January 04, 2002

ImmunoGen, Inc. Receives Patent on Production of DM1
November 28, 2001

Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement

Show per page

Who we are

Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2025 ESG report

Key Facts

Get a closer look at our impact.
Learn more

Annual report

See our latest 2025 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?